These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34698568)

  • 1. Deep Learning for Prediction of N2 Metastasis and Survival for Clinical Stage I Non-Small Cell Lung Cancer.
    Zhong Y; She Y; Deng J; Chen S; Wang T; Yang M; Ma M; Song Y; Qi H; Wang Y; Shi J; Wu C; Xie D; Chen C;
    Radiology; 2022 Jan; 302(1):200-211. PubMed ID: 34698568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomics for Survival Risk Stratification of Clinical and Pathologic Stage IA Pure-Solid Non-Small Cell Lung Cancer.
    Wang T; She Y; Yang Y; Liu X; Chen S; Zhong Y; Deng J; Zhao M; Sun X; Xie D; Chen C
    Radiology; 2022 Feb; 302(2):425-434. PubMed ID: 34726531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics study.
    Hosny A; Parmar C; Coroller TP; Grossmann P; Zeleznik R; Kumar A; Bussink J; Gillies RJ; Mak RH; Aerts HJWL
    PLoS Med; 2018 Nov; 15(11):e1002711. PubMed ID: 30500819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer.
    Huang Y; Liu Z; He L; Chen X; Pan D; Ma Z; Liang C; Tian J; Liang C
    Radiology; 2016 Dec; 281(3):947-957. PubMed ID: 27347764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of a Deep Learning Model for Non-Small Cell Lung Cancer Survival.
    She Y; Jin Z; Wu J; Deng J; Zhang L; Su H; Jiang G; Liu H; Xie D; Cao N; Ren Y; Chen C
    JAMA Netw Open; 2020 Jun; 3(6):e205842. PubMed ID: 32492161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/CT based cross-modal deep learning signature to predict occult nodal metastasis in lung cancer.
    Zhong Y; Cai C; Chen T; Gui H; Deng J; Yang M; Yu B; Song Y; Wang T; Sun X; Shi J; Chen Y; Xie D; Chen C; She Y
    Nat Commun; 2023 Nov; 14(1):7513. PubMed ID: 37980411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel deep learning prognostic system improves survival predictions for stage III non-small cell lung cancer.
    Yang L; Fan X; Qin W; Xu Y; Zou B; Fan B; Wang S; Dong T; Wang L
    Cancer Med; 2022 Nov; 11(22):4246-4255. PubMed ID: 35491970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
    Zhang N; Liang R; Gensheimer MF; Guo M; Zhu H; Yu J; Diehn M; Loo BW; Li R; Wu J
    Theranostics; 2020; 10(25):11707-11718. PubMed ID: 33052242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative CT-based Deep Learning Model for Predicting Disease-Free Survival in Patients with Lung Adenocarcinomas.
    Kim H; Goo JM; Lee KH; Kim YT; Park CM
    Radiology; 2020 Jul; 296(1):216-224. PubMed ID: 32396042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
    Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.
    Chen DT; Hsu YL; Fulp WJ; Coppola D; Haura EB; Yeatman TJ; Cress WD
    J Natl Cancer Inst; 2011 Dec; 103(24):1859-70. PubMed ID: 22157961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nomogram to predict the survival of stage IIIA-N2 non-small cell lung cancer after surgery.
    Mao Q; Xia W; Dong G; Chen S; Wang A; Jin G; Jiang F; Xu L
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1784-1792.e3. PubMed ID: 29554790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study.
    Jiang Y; Liang X; Han Z; Wang W; Xi S; Li T; Chen C; Yuan Q; Li N; Yu J; Xie Y; Xu Y; Zhou Z; Poultsides GA; Li G; Li R
    Lancet Digit Health; 2021 Jun; 3(6):e371-e382. PubMed ID: 34045003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.
    Boros A; Lacroix L; Lacas B; Adam J; Pignon JP; Caramella C; Planchard D; de Montpreville V; Deutsch E; Levy A; Besse B; Le Pechoux C
    Oncotarget; 2017 Apr; 8(15):25189-25199. PubMed ID: 28445990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly expressed mRNA signature for predicting survival in patients with stage I/II non-small-cell lung cancer after operation.
    Ma N; Si L; Yang M; Li M; He Z
    Sci Rep; 2021 Mar; 11(1):5855. PubMed ID: 33712694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Unexpected N2 Disease Associated With Clinical T1-2N0-1M0 Non-Small-Cell Lung Cancer.
    Kamigaichi A; Tsutani Y; Mimae T; Miyata Y; Shimada Y; Ito H; Nakayama H; Ikeda N; Okada M
    Clin Lung Cancer; 2021 Mar; 22(2):120-126.e3. PubMed ID: 33485802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.